Evolving Treatment Landscape With Regorafenib and TAS-102 in Metastatic Colorectal Cancer

In this episode, Nilofer S. Azad, MD, and Kanwal Raghav, MD, discuss current and emerging uses of regorafenib and TAS-102 in later-line treatment of patients with mCRC, with topics including:Current use of regorafenib and TAS-102 monotherapyCombination therapy with regorafenib and PD-1 inhibitorsAdding bevacizumab to TAS-102Presenters:Nilofer S. Azad, MD  Professor, Oncology  Sidney Kimmel Comprehensive Cancer Center  Johns Hopkins UniversityBaltimore, Maryland  Kanwal Raghav, MDAssociate Professor, GI Medical Oncology  University of Texas MD Anderson Cancer CenterHouston, Texas  Content based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Follow along with the slideset:https://bit.ly/3NLejWeLink to full program:https://bit.ly/33yrIyh